[1] Nakamura H, Ueki Y, Sakito S, et al. Clinical effects of actarit in rheumatoid arthritis: improvement of early disease activity mediated by reduction of serum concentrations of nitric oxide[J]. Clin Exp Rheumatol, 2000, 18(4):445-450.
[2] Takeba Y, Suzuki N, Wakisaka S, et al. Effects of actarit on synovial cell functions in patients with rheumatoid arthritis[J]. J Rheumatol, 1999, 26(1):25-33.
[3] Fujisawa H, Nishimura T, Inaba M, et al. Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches[J]. Int J Immunopharmacol, 1995, 17(7):611-617.
[4] Kawai K, Kobayashi Y, Hirayama M, et al. Suppressive effects of 4-acetylaminophenylacetic acid (actarit) on experimental autoimmune encephalomyelitis in rats[J]. Immunopharmacology, 1998, 39(2):127-138.
[5] 张运芳,李 俊,金 涌,等. 血浆阿克他利的高效液相色谱检测[J]. 安徽医药,2001,5(3):212-213.
[6] Fang F, Xu G, Lu B. HPLC determination of 4-acetylaminophenylacetic acid[J]. J Liq Chromtogr Rel Technol, 2001, 24(2):1021-1027.
[7] Huang Y, Shi R, Gee W, et al. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management[J]. Bioanalysis, 2012, 4(15):1919-1931.
[8] Ye J, Wang Q, Zhou X, et al. Injectable actarit-loaded solid lipid nanoparticles as passive targeting therapeutic agents for rheumatoid arthritis[J]. Int J Pharm, 2008, 352(1-2):273-279.
[9] Loya P, Saraf MN. Determination of actarit from human plasma for bioequivalence studies[J]. Indian J Pharm Sci, 2010, 72(6):726-731.